CA2789515A1 - Treatment of chronic inflammatory conditions - Google Patents

Treatment of chronic inflammatory conditions Download PDF

Info

Publication number
CA2789515A1
CA2789515A1 CA2789515A CA2789515A CA2789515A1 CA 2789515 A1 CA2789515 A1 CA 2789515A1 CA 2789515 A CA2789515 A CA 2789515A CA 2789515 A CA2789515 A CA 2789515A CA 2789515 A1 CA2789515 A1 CA 2789515A1
Authority
CA
Canada
Prior art keywords
agent
alpha
patient
binding molecule
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2789515A
Other languages
English (en)
French (fr)
Inventor
Gino Luigi Vairo
John Allan Hamilton
Andrew David Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
University of Melbourne
Original Assignee
CSL Ltd
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd, University of Melbourne filed Critical CSL Ltd
Priority claimed from PCT/AU2010/000178 external-priority patent/WO2010094068A1/en
Publication of CA2789515A1 publication Critical patent/CA2789515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
CA2789515A 2010-02-18 2010-02-18 Treatment of chronic inflammatory conditions Abandoned CA2789515A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2010/000178 WO2010094068A1 (en) 2009-02-18 2010-02-18 Treatment of chronic inflammatory conditions

Publications (1)

Publication Number Publication Date
CA2789515A1 true CA2789515A1 (en) 2010-08-26

Family

ID=47073567

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2789515A Abandoned CA2789515A1 (en) 2010-02-18 2010-02-18 Treatment of chronic inflammatory conditions

Country Status (4)

Country Link
JP (1) JP2013519689A (ja)
KR (1) KR20130032866A (ja)
CN (1) CN102821815A (ja)
CA (1) CA2789515A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053619T2 (hu) * 2015-06-29 2021-07-28 Immunogen Inc Anti-CD123 antitestek és konjugátumok és ezek származékai

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103932T1 (de) * 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
EP1497327A2 (en) * 2002-04-17 2005-01-19 Novartis AG Method for the identification of inhibitors of the binding of are-containing mrna and an hur protein
EA201070687A1 (ru) * 2007-12-06 2010-12-30 Си Эс Эл ЛИМИТЕД Способ ингибирования лейкозных стволовых клеток

Also Published As

Publication number Publication date
CN102821815A (zh) 2012-12-12
JP2013519689A (ja) 2013-05-30
KR20130032866A (ko) 2013-04-02

Similar Documents

Publication Publication Date Title
US20150017180A1 (en) Treatment of chronic inflammatory conditions
US20210301028A1 (en) Composition and methods for anti-tnfr2 antibodies
WO2020088605A1 (zh) 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
JP7050041B2 (ja) 抗アルファ２インテグリン抗体及びそれらの使用
AU2009303318B2 (en) TCR complex immunotherapeutics
JP5426531B2 (ja) 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
AU2019264579A1 (en) Interleukin-2 fusion proteins and uses thereof
EP3802606A2 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
JP5960756B2 (ja) 自己免疫疾患の治療のためのＢＬｙＳ阻害剤および抗ＣＤ２０剤の組合せ
AU2022259766B2 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
JP6917368B2 (ja) 一本鎖ｃｄ２７受容体アゴニストタンパク質
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
JP6018507B2 (ja) Ｉ型インターフェロン産生細胞を標的化するための組成物及び方法
CA2789515A1 (en) Treatment of chronic inflammatory conditions
KR20240019786A (ko) Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
KR20230104611A (ko) 항-cd94 항체 및 이의 사용 방법
EP4132582A1 (en) Targeted reduction of activated immune cells
Ochi Mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy
WO2023094698A1 (en) Specific antagonist anti-sirpg antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160218